Related Experiment Video
Updated: Jan 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Pembrolizumab treatment of prostate cancer]
Anne Hauge Thostrup1,2, Andreas Carus3, Morten Ladekarl3
1Klinisk Farmakologisk Enhed, Aalborg Universitetshospital.
Abstract:
In this case report, a 73-year-old male with metastatic prostate cancer is presented. After progression on available standard treatments, he was enrolled in a precision medicine program. Re-biopsy revealed a defect in mismatch repair and an Activin A receptor type 2A mutation associated with high microsatellite instability. Pembrolizumab was started with clinical response, tumor regression, PSA-decline, and no adverse reactions. After 5 months, the treatment is ongoing. This illustrates that pembrolizumab can have an effect in some patients with prostate cancer and underscores the importance of molecular diagnostics.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...

